Cargando…
Platinum-Taxol non-cross resistance in epithelial ovarian cancer.
The aim of this study was to assess the clinical evidence for platinum-Taxol non-cross-resistance in patients with epithelial ovarian cancer. Unlike other studies, only patients who had demonstrably progressive disease on platinum therapy were analysed. Patients received 135-200 mg m-2 of Taxol over...
Autores principales: | Gore, M. E., Preston, N., A'Hern, R. P., Hill, C., Mitchell, P., Chang, J., Nicolson, M. |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
1995
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2033816/ https://www.ncbi.nlm.nih.gov/pubmed/7779729 |
Ejemplares similares
-
Leptin contributes to the taxol chemoresistance in epithelial ovarian cancer
por: Gu, Fei, et al.
Publicado: (2019) -
Taxol: an important new drug in the management of epithelial ovarian cancer.
por: Markman, M.
Publicado: (1991) -
Paclitaxel (Taxol) in relapsed and refractory ovarian cancer: the UK and Eire experience.
por: Gore, M. E., et al.
Publicado: (1995) -
Protracted oral etoposide in epithelial ovarian cancer: a phase II study in patients with relapsed or platinum-resistant disease.
por: Seymour, M. T., et al.
Publicado: (1994) -
Surgery in platinum-resistant recurrent epithelial ovarian carcinoma
por: Zhao, Ling-Qin, et al.
Publicado: (2022)